^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19-CD34t metabolically programmed CAR transduced T-cells

    i
    Other names: CD19-CD34t metabolically programmed CAR transduced T-cells
    Associations

    News

    Trials
    Company:
    Medical University of South Carolina
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1/2
    Enrollment open • Phase classification • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
    over1year
    Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
    P1b, N=27, Not yet recruiting, Medical University of South Carolina | Trial completion date: Feb 2026 --> Dec 2026 | Initiation date: Apr 2023 --> Aug 2023 | Trial primary completion date: Feb 2025 --> Aug 2025
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
    almost2years
    Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
    P1b, N=27, Not yet recruiting, Medical University of South Carolina
    New P1 trial • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells